AAMU
RCUS icon

Amundi Asset Management US’s Arcus Biosciences RCUS Stock Holding History

Amundi Asset Management US’s Portfolio RCUS Stock Details RCUS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-4,445
Closed -$69K – 1614
2018
Q1 		$69K Buy
+4,445
New +$74K ﹤0.01% 1463

Other funds holding RCUS

AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
FCMI
Foresite Capital Management III Larkspur, California $37.9M AUM 6.87% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
HIM
Hillhouse Investment Management Grand Cayman, Cayman Islands $3.13B AUM 7.29% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BOTOTLSJU
Board of Trustees of The Leland Stanford Junior University Redwood City, California $849M AUM 55.45% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Amundi Asset Management US's RCUS Position: Q2 2018 in Review

Amundi Asset Management US sold out of Arcus Biosciences (RCUS) in Q2 2018, closing a stake of 4,445 shares — an estimated $69K sold.

Amundi Asset Management US first reported a position in RCUS in Q1 2018 and held it in 1 quarter. The position peaked at $69K in Q1 2018. 64 funds tracked by Wall St. Rank hold RCUS as of Q2 2018.

  • Amundi Asset Management US reported no remaining Arcus Biosciences position as of Q2 2018 after selling out during the quarter.
  • Amundi Asset Management US sold 4,445 Arcus Biosciences shares in Q2 2018, an estimated $69K.
  • Amundi Asset Management US first reported a position in Arcus Biosciences in Q1 2018 and held it in 1 quarter.
  • Amundi Asset Management US's Arcus Biosciences position peaked at $69K in Q1 2018.
  • 64 funds tracked by Wall St. Rank held Arcus Biosciences as of Q2 2018.

Based on Amundi Asset Management US's 13F filing for Q2 2018, filed 13 Aug 2018.